Resmed – Algo Buy
ResMed is under Algo Engine buy conditions and we see buying support building.
ResMed will release 2Q21 earnings on Friday 29 January.

ResMed is under Algo Engine buy conditions and we see buying support building.
ResMed will release 2Q21 earnings on Friday 29 January.

Fisher & Paykel Healthcare Corporation is under Algo Engine buy conditions and is now consolidating above the $30 support level.
Investors should consider a buy-write strategy to enhance the income return. For more detail please call our office on 1300 614 002.

ASX is under Algo Engine buy conditions and is now likely to find buying support.

Ansell is under Algo Engine buy conditions and we see support building within the $33 – $36 level.
ANN goes ex-div $0.33 on 24 Feb.
Subscribers to our Options Pro service should look at buying the Feb $34.50 calls as a leveraged exposure. For more detail on our strategy, please call 1300 614 002.

ResMed is under Algo Engine buy conditions and we see buying support building.
ResMed will release 2Q21 earnings on Friday 29 January.

ASX is under Algo Engine buy conditions and is now likely to find buying support.

Ansell is under Algo Engine buy conditions and we see support building within the $33 – $36 level.
ANN goes ex-div $0.33 on 24 Feb.
Subscribers to our Options Pro service should look at buying the Feb $34.50 calls as a leveraged exposure. For more detail on our strategy, please call 1300 614 002.

Amcor is under Algo Engine buy conditions and is a current holding in our ASX 100 model portfolio.
Amcor goes ex-div $0.17 on 3 March.

Ramsay Health Care is under Algo Engine buy conditions and is a current holding in our model portfolio.

{NYS:C} reported Q4 earnings which showed a 10% fall in revenue and 7% fall in profit.
The release of $1.5bn in reserves for credit losses helps to pad the numbers, as did the potential one-off boost from growth in trading and investment-related income.
In 2021 we remain concerned about credit quality deterioration and risks to non-repeatable investment-related income growth, both likely to negatively impact returns.
The company share buyback program will offer some downside protection and we’ll look to enter the trade from the long side, at lower price levels.
For the time being, we sit on the short side of the Citi trade.

